Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction
Top Cited Papers
- 28 March 2002
- journal article
- clinical trial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 346 (13), 957-966
- https://doi.org/10.1056/nejmoa013404
Abstract
As compared with thrombolytic therapy, primary percutaneous transluminal coronary angioplasty (PTCA) in acute myocardial infarction reduces the rates of death, reinfarction, and stroke, but recurrent ischemia, restenosis, and reocclusion of the infarct-related artery remain problematic. When used in combination with PTCA, coronary stenting and platelet glycoprotein IIb/IIIa inhibitors may further improve outcomes. Using a 2-by-2 factorial design, we randomly assigned 2082 patients with acute myocardial infarction to undergo PTCA alone (518 patients), PTCA plus abciximab therapy (528), stenting alone with the MultiLink stent (512), or stenting plus abciximab therapy (524). Normal flow was restored in the target vessel in 94.5 to 96.9 percent of patients and did not vary according to the reperfusion strategy. At six months, the primary end point — a composite of death, reinfarction, disabling stroke, and ischemia-driven revascularization of the target vessel — had occurred in 20.0 percent of patients after PTCA, 16.5 percent after PTCA plus abciximab, 11.5 percent after stenting, and 10.2 percent after stenting plus abciximab (P<0.001). There were no significant differences among the groups in the rates of death, stroke, or reinfarction; the difference in the incidence of the primary end point was due entirely to differences in the rates of target-vessel revascularization (ranging from 15.7 percent after PTCA to 5.2 percent after stenting plus abciximab, P<0.001). The rate of angiographically established restenosis was 40.8 percent after PTCA and 22.2 percent after stenting (P<0.001), and the respective rates of reocclusion of the infarcted-related artery were 11.3 percent and 5.7 percent (P=0.01), both independent of abciximab use. At experienced centers, stent implantation (with or without abciximab therapy) should be considered the routine reperfusion strategy.Keywords
This publication has 38 references indexed in Scilit:
- Long-Term Benefit of Primary Angioplasty as Compared with Thrombolytic Therapy for Acute Myocardial InfarctionThe New England Journal of Medicine, 1999
- Clinical and Angiographic Follow-Up After Primary Stenting in Acute Myocardial InfarctionCirculation, 1999
- Long-term outcome after primary angioplasty: report from the Primary Angioplasty in Myocardial Infarction (PAMI-I) trialJournal of the American College of Cardiology, 1999
- Randomized Comparison of Coronary Stenting With Balloon Angioplasty in Selected Patients With Acute Myocardial InfarctionCirculation, 1998
- Stent implantation in acute myocardial infarction using a heparin-coated stent: a pilot study as a preamble to a randomized trial comparing balloon angioplasty and stentingInternational Journal of Cardiovascular Interventions, 1998
- Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative reviewJAMA, 1997
- Analysis of the Relative Costs and Effectiveness of Primary Angioplasty Versus Tissue-Type Plasminogen Activator: The Primary Angioplasty in Myocardial Infarction (PAMI) TrialJournal of the American College of Cardiology, 1997
- Primary stent implantation without coumadin in acute myocardial infarctionJournal of the American College of Cardiology, 1996
- A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarctionThe American Journal of Cardiology, 1995
- Implications of recurrent ischemia after reperfusion therapy in acute myocardial infarction: A comparison of thrombolytic therapy and primary angioplastyJournal of the American College of Cardiology, 1995